Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Connect Biopharma Holdings Ltd ADR (NQ: CNTB ) 1.110 -0.070 (-5.93%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Connect Biopharma Holdings Ltd ADR Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum July 01, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) June 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces New Leadership and Chair of the Board of Directors June 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma May 22, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma May 07, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update April 16, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference March 19, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors February 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma December 12, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023 December 11, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management November 30, 2023 Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... Via Newsfile Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China November 21, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis November 21, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023 November 20, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update September 12, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement September 12, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Participate in Upcoming September Investor Conferences August 24, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology July 10, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Participate in the SVB Securities Therapeutics Forum July 05, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis June 01, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update April 11, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms March 18, 2023 From Connect Biopharma Holdings Limited Via Business Wire Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions March 17, 2023 From Connect Biopharma Holdings Limited Via Business Wire Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting March 06, 2023 From Connect Biopharma Holdings Limited Via Business Wire Connect Biopharma To Present at Upcoming Investor and Scientific Conferences October 27, 2022 From Connect Biopharma Holdings Limited Via GlobeNewswire CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China October 04, 2022 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China October 04, 2022 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis October 03, 2022 From Connect Biopharma Holdings Limited Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.